Thalidomide, A Rational Agent for Treatment of Multicentric Reticulohistiocytosis
Publication/Presentation Date
4-2019
Abstract
A patient with Multifocal Reticulohistiocytosis (MRH) of skin and joints failed treatment with etanercept, methotrexate, hydroxychloroquine, prednisone, bisphosphonates and hydroxyzine. Long term treatment with thalidomide led to marked improvement in joint and cutaneous manifestations.
Volume
4
Issue
1
First Page
1
Last Page
3
ISSN
2684-124X
Published In/Presented At
Zinn DJ, Eckstein O, Olsen ML, Allen CE, McClain KL (2019) Thalidomide, A Rational Agent for Treatment of Multicentric Reticulohistiocytosis. Dermatol Case Rep 4: 152.
Disciplines
Hematology | Medicine and Health Sciences | Oncology | Pediatrics
PubMedID
32529194
Peer Reviewed for front end display
Peer-Reviewed
Department(s)
Department of Pediatrics, Department of Pediatrics Faculty
Document Type
Article
COinS